Status:
COMPLETED
Cohort Study of Efficacy and Safety of Interferon Intermittent Treatment of Chronic Hepatitis B
Lead Sponsor:
Beijing Ditan Hospital
Conditions:
Chronic Hepatitis B
Eligibility:
All Genders
18-75 years
Brief Summary
This study was a retrospective clinical observational cohort study. All patients with chronic hepatitis B (CHB) whose HBsAg decreased by less than 10% were treated continuously with interferon in the ...
Detailed Description
This study was a retrospective clinical observational cohort study. All patients with chronic hepatitis B (CHB) whose HBsAg decreased by less than 10% were treated continuously with interferon in the ...
Eligibility Criteria
Inclusion
- All patients with chronic hepatitis B meet the diagnostic criteria of China Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2015)
Exclusion
- coinfection with other viruses including HCV, HDV, and HIV;
- syphilis antibody positive;
- co-exist other liver diseases including alcoholic liver disease, metabolic liver disease, fatty liver, drug induce liver injury, and autoimmune liver disease;
- complication of cirrhosis or liver cancer.
Key Trial Info
Start Date :
June 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2019
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04028856
Start Date
June 1 2018
End Date
June 30 2019
Last Update
July 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
liver disease center, Beijing Ditan Hospital
Beijing, Beijing Municipality, China, 100015